PRN Stock Overview
Operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Profound Medical Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$10.68 |
52 Week High | CA$16.00 |
52 Week Low | CA$9.55 |
Beta | 0.80 |
11 Month Change | -7.53% |
3 Month Change | -10.18% |
1 Year Change | -21.47% |
33 Year Change | -39.86% |
5 Year Change | 24.19% |
Change since IPO | -28.80% |
Recent News & Updates
Recent updates
Does Profound Medical (TSE:PRN) Have A Healthy Balance Sheet?
May 03Is Profound Medical (TSE:PRN) Using Debt In A Risky Way?
Sep 15Will Profound Medical (TSE:PRN) Spend Its Cash Wisely?
Sep 07Here's Why We're Not Too Worried About Profound Medical's (TSE:PRN) Cash Burn Situation
Jan 07We Think Profound Medical (TSE:PRN) Can Easily Afford To Drive Business Growth
Jul 02We Take A Look At Why Profound Medical Corp.'s (TSE:PRN) CEO Compensation Is Well Earned
May 13Analysts Expect Breakeven For Profound Medical Corp. (TSE:PRN) Before Long
May 07We Think Profound Medical (TSE:PRN) Can Afford To Drive Business Growth
Mar 25Shareholder Returns
PRN | CA Medical Equipment | CA Market | |
---|---|---|---|
7D | -0.5% | 0.3% | 0.6% |
1Y | -21.5% | -11.3% | 23.3% |
Return vs Industry: PRN underperformed the Canadian Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: PRN underperformed the Canadian Market which returned 23.4% over the past year.
Price Volatility
PRN volatility | |
---|---|
PRN Average Weekly Movement | 6.7% |
Medical Equipment Industry Average Movement | 10.5% |
Market Average Movement | 8.3% |
10% most volatile stocks in CA Market | 17.2% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: PRN has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: PRN's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 131 | Arun Menawat | www.profoundmedical.com |
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors.
Profound Medical Corp. Fundamentals Summary
PRN fundamental statistics | |
---|---|
Market cap | CA$263.67m |
Earnings (TTM) | -CA$37.45m |
Revenue (TTM) | CA$10.70m |
24.4x
P/S Ratio-7.0x
P/E RatioIs PRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
PRN income statement (TTM) | |
---|---|
Revenue | US$7.88m |
Cost of Revenue | US$3.05m |
Gross Profit | US$4.83m |
Other Expenses | US$32.42m |
Earnings | -US$27.59m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.13 |
Gross Margin | 61.24% |
Net Profit Margin | -350.14% |
Debt/Equity Ratio | 15.2% |
How did PRN perform over the long term?
See historical performance and comparison